SCHEMBL5827697

SCHEMBL5827697

COc1ccc(Br)cc1C1(C)CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 2/20 0.50
RARB P10826 2/20 0.50
RARG P13631 2/20 0.50
KDM4E B2RXH2 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 1/20 0.43
PTGDR Q13258 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.42
GAA P10253 1/20 0.40
LMNA P02545 2/20 0.38
KDM1A O60341 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
KDM1B Q8NB78 1/20 0.35
EHMT2 Q96KQ7 1/20 0.35
TSHR P16473 1/20 0.35
GLA P06280 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20819648 0.91 ALDH1A1 (0.46) RARARARBRARGKDM4ETDP1
SCHEMBL6619475 0.79 PTGDR (0.37) RARARARBRARGKDM4ETDP1
SCHEMBL10392057 0.78 KDM4E (0.43) KDM4ETDP1GAALMNAKDM1A
SCHEMBL11212605 0.78 MEN1 (0.42) KDM4ETDP1MEN1KMT2AGAA
SCHEMBL17847413 0.78 PTGDR (0.44) RARARARBRARGKDM4ETDP1
SCHEMBL4883529 0.77 RARB (0.48) RARARARBRARGALDH1A1PTGDR
SCHEMBL4573426 0.77 ALDH1A1 (0.42) KDM4ETDP1MEN1KMT2AALDH1A1
SCHEMBL7786872 0.77 CCR5 (0.50) ALDH1A1PTGDRPTGDR2LMNAMAOB
SCHEMBL4886176 0.77 PTGDR2 (0.73) RARARARBRARGTDP1MEN1
SCHEMBL9489414 0.76 RARA (0.57) RARARARBRARGKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7153875-B2 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases INCYTE SAN DIEGO (US) 2006-12-26 US disclosed
EP-1385465-A4 HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES INCYTE SAN DIEGO INC (US) 2005-09-07 EP disclosed
EP-1385465-A2 HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES Incyte San Diego, Inc. (US) 2004-02-04 EP disclosed
US-20020143182-A1 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases INCYTE GENOMICS, INC. 2002-10-03 US disclosed
WO-2002072009-A2 HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES MAXIA PHARMACEUTICALS, INC. (US) 2002-09-19 WO disclosed
US-5212203-A Skin disorders CENTRE INTERNATIONAL DE RECHERCHES DERMATOGOLOGIQUES (C.I.R.D.) (FR) 1993-05-18 US disclosed
EP-0325540-B1 AROMATIC ESTERS AND THIOESTERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN OR ANIMAL THERAPEUTICS AND IN COSMETICS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) 1993-04-14 EP disclosed
EP-0232199-B1 AROMATIC BENZAMIDO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AS WELL AS IN COSMETICS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) 1993-02-03 EP disclosed
US-5173289-A Skin disorders, antiinflammatory agents CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (C.I.R.D.) (FR) 1992-12-22 US disclosed
US-4927928-A SKIN DISORDERS, EYES, ANTITUMOR CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) 1990-05-22 US disclosed
US-4925658-A TREATMENT OF DERMATOLOGIC, RHEUMATIC, RESPIRATORY, OPHTHALMOLOGIC DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) 1990-05-15 US disclosed
EP-0325540-A1 Aromatic esters and thioesters, process for their preparation and their use in human or animal therapeutics and in cosmetics CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) 1989-07-26 EP disclosed
EP-0232199-A2 Aromatic benzamido compounds, process for their preparation and their use in human or veterinary medicine as well as in cosmetics CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) 1987-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143182-A1 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases CCNY, HRAS, AHR RARA 1460/4885RARB 1465/4885RARG 1374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.